Disease Overview：Lymphoma（LYM）
Lymphoma is a heterogeneous group of hematologic malignancies originating from lymphoid tissue—primarily B-cells, though T-cell and NK-cell subtypes also occur. Classified broadly into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), it encompasses over 100 distinct entities with varying clinical behavior, molecular drivers, and prognostic implications. Diagnosis relies on integrated assessment: histopathology with immunohistochemistry, flow cytometry, molecular profiling (e.g., FISH, NGS), and staging via PET/CT and bone marrow biopsy. Treatment is risk-adapted and modality-specific—ranging from chemoimmunotherapy (e.g., R-CHOP for diffuse large B-cell lymphoma) to targeted agents (BTK inhibitors, PI3K inhibitors), immunomodulators (lenalidomide), bispecific antibodies, CAR-T cell therapy, and consolidative radiotherapy or stem cell transplantation. Prognosis varies widely; early-stage HL achieves >90% five-year survival, while aggressive NHL subtypes require precise risk stratification and access to novel therapeutics.
China offers compelling advantages for lymphoma care: nationally certified lymphoma centers—many affiliated with top-tier academic hospitals—employ multidisciplinary tumor boards led by hematologists specializing in lymphoid malignancies. Advanced diagnostics include next-generation sequencing platforms and quantitative PET/CT with SUVmax analysis. China has pioneered real-world implementation of domestically developed CAR-T therapies (e.g., relmacabtagene autoleucel) and participates in global phase III trials for bispecifics and antibody-drug conjugates. Five-year progression-free survival rates for high-risk DLBCL align closely with Western benchmarks, supported by robust longitudinal registry data. Crucially, treatment costs—including comprehensive diagnostic workup, standard chemoimmunotherapy, and approved cellular therapies—are typically 40–60% lower than in the US or Western Europe, without compromising clinical rigor or regulatory oversight (NMPA-approved protocols).
As a dedicated medical tourism agency, we facilitate seamless international patient journeys: pre-travel eligibility verification, direct coordination with NMPA-accredited lymphoma centers, transparent itemized pricing (all-inclusive packages covering diagnostics, treatment, accommodation, and interpreter services), and end-to-end support—from visa assistance and airport transfers to post-discharge follow-up coordination. Our clinical liaisons—board-certified oncology nurses fluent in English and Mandarin—ensure continuity of care and timely communication with treating physicians.
Lymphoma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Lymphoma (Hematology/Oncology)
Non-Surgical/Medical Therapies
*Indicated for most lymphomas (DLBCL, FL, MCL, HL), based on histology, stage, IPI score, and molecular markers.*
- •First-Line Chemotherapy (R-CHOP)
- *Cost per cycle (USD):* $1,850–$2,300 - Rituximab (375 mg/m²): $1,120 - Cyclophosphamide, Doxorubicin, Vincristine, Prednisone: $480 - Infusion & nursing: $250
- •Targeted Therapy (BTK Inhibitors – e.g., Ibrutinib)
- *Monthly cost (USD):* $3,900–$4,200 (oral, 28-day supply)
- •Immunomodulatory Agents (Lenalidomide)
- *Monthly cost (USD):* $2,600–$2,900
- •Diagnostic & Monitoring Labs/Exams (per cycle or baseline)
- Bone marrow biopsy + flow cytometry: $410 - LDH, CBC, comprehensive metabolic panel: $125 - Serum free light chains & immunofixation: $190
Surgical/Procedural/Interventional Options
*Surgery is rarely curative but used diagnostically or for palliation in specific scenarios.*
- •Diagnostic Lymph Node Excisional Biopsy
- *Procedure cost (USD):* $1,450–$1,750 - OR time, anesthesia, pathology (H&E + IHC + molecular): $1,220 - Surgeon fee: $230
- •Debulking Surgery (Rare)
- *Cost (USD):* $4,800–$6,200 - Pre-op workup (EKG, chest X-ray, coagulation panel): $180 - OR, anesthesia, ICU monitoring (1 day): $4,620
Special/Complex Condition Management
- •Autologous Stem Cell Transplant (ASCT)
- *Total cost (USD):* $28,500–$34,000 - Mobilization (G-CSF + plerixafor): $3,200 - Apheresis & cryopreservation: $2,100 - Conditioning (BEAM or TBI-based): $11,800 - Transplant admission (14–21 days): $11,400
- •CAR-T Therapy (e.g., Relma-cel)
- *Cost (USD):* $128,000–$142,000 (includes leukapheresis, manufacturing, infusion, 30-day monitoring)
Quick Selection Guide
- •<60 years, fit, newly diagnosed DLBCL: Start R-CHOP ($1,850/cycle × 6 = ~$11,100); add PET-CT ($680) for interim response assessment.
- •>75 years or frail with FL: Rituximab monotherapy ($1,120/cycle × 4 = $4,480) + lenalidomide ($2,600/month × 6 = $15,600) — lower toxicity, moderate budget.
- •Relapsed DLBCL, high IPI, budget >$100K: CAR-T ($128K+) offers best long-term remission odds.
- •R/R MCL with *TP53* mutation: Prioritize BTK inhibitor ($3,900/month) over ASCT due to poor transplant outcomes.
- •Bulky symptomatic mass with airway compromise: Urgent excisional biopsy + debulking ($4,800–$6,200) followed by bridging chemo.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Lymphoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Lymphoma treatment with China top medical destinations:
